Countable PCR delivers single-molecule precision for Europe's most demanding quantification challenges — from cell and gene therapy manufacturing to biomarker validation, diagnostics, commercial ...

Northwestern scientists have created the fastest-ever hepatitis C diagnostic, delivering accurate results in only 15 minutes. The test uses the DASH rapid PCR system, originally developed for COVID, ...

Roche has secured regulatory green lights in both the U.S. and Europe to begin shipping its first point-of-care test for whooping cough amid a worldwide surge in cases and the recent deaths of infants ...

Late-night cravings aren’t the only thing DoorDash can help with. Starting this week, women can order a first-of-its-kind, at-home swab test for three common sexually transmitted infections and have ...

Scientists at the ICAR-Central Institute of Fisheries Education, Mumbai, have developed a species-specific PCR test 1 that can rapidly and accurately detect Cronobacter sakazakii, a food-borne ...

As we get into another winter holiday season, COVID is still part of our lives. And although it's hard to predict exactly what this year's cold, flu and coronavirus season will look like, experts want ...

Patients in rural communities often lack timely access to innovative infectious disease testing because diagnostic laboratories are located far away. Long transport times and logistical barriers delay ...

A new biotechnology company in McKinney has ambitions to become the world’s first fully integrated platform for polymerase chain reaction (PCR) testing — the same technology behind a common COVID-19 ...

An expert panel convened by the nation’s top post-acute care medical organization has recommended against the routine use of urine PCR tests to diagnose urinary tract infections. Such tests have ...

The COVID-19 pandemic yielded important advances in testing for respiratory viruses, but it also exposed important unmet needs in screening to prevent the spread of infections in high-risk settings.

Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors. Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A ...